




RESEARCH REPORT



OTC/DTC INFECTIOUS DISEASE DIAGNOSTICS

Strategies and Trends. **COVID-19 Adjusted Forecasts** by Application by Channel by Country. With Market Analysis, Executive Guides, Customization and **COVID-19 Market Opportunity Analysis**

2021 to 2025



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

- i. Market Guides20
 - iA. Situation Analysis and COVID-19 Market Analysis 21
 - iB. Guide for Executives and Marketing Staff 23
 - iC. Guide for Investment Analysts and Management Consultants..... 24
- 1. Introduction and Market Definition25
 - 1.1 What is OTC and DTC Testing? 26
 - 1.2 OTC/DTC Testing – the quiet revolution in diagnostics 27
 - 1.3 Self vs. Send – who knew? 28
 - 1.4 Market Definition 29
 - 1.4.1 Retail vs. Wholesale 29
 - 1.4.2 OTC, DTC, HxV and HSG 29
 - 1.4.3 Currency 30
 - 1.4.4 Years 30
 - 1.5 Methodology 31
 - 1.5.1 Authors 31
 - 1.5.2 Sources 31
 - 1.6 U.S. Medical Market and Clinical Laboratory Testing - Perspective..... 32
 - 1.6.1 U.S. Medicare Expenditures for Clinical Testing 33
- 2. The Infectious Diseases – Guide to the Pathogens35
 - 2.1 HIV - Human Immunodeficiency Virus (AIDS) 36
 - 2.1.1 Virology 36
 - 2.1.1.1 Classification 36
 - 2.1.1.2 Structure and genome 37

2.1.1.3 Tropism 39

2.1.1.4 Replication cycle 41

2.1.1.5 Genetic variability 47

2.1.2 Diagnosis 49

2.1.3 Testing..... 50

 2.1.3.1 Antibody tests 50

 2.1.3.2 Point of Care Tests (POCT) 53

 2.1.3.4 Antigen Tests 55

 2.1.3.5 Nucleic acid-based tests (NAT)..... 56

 2.1.3.6 Other tests used in HIV treatment 57

2.2 HBV – Hepatitis B 59

 2.2.1 Virology 60

 2.2.1.1 Genome..... 61

 2.2.1.2 Pathogenesis 62

 2.2.1.3 Hepatitis B virus replication 62

 2.2.1.4 Serotypes and genotypes 63

 2.2.2 Mechanisms..... 63

 2.2.3 Diagnosis 64

 2.2.4 Market Opportunity Analysis..... 65

2.3 HCV – Hepatitis C 67

 2.3.1 Taxonomy..... 68

 2.3.2.1 Structure 68

 2.3.2.2 Genome..... 69

 2.3.3 Molecular biology 70

 2.3.4 Replication..... 71

 2.3.5 Genotypes 73

- 2.3.5.1 Clinical importance 73
- 2.3.6 Market Opportunity Analysis..... 74
- 2.4 HPV - Human papillomavirus 76
 - 2.4.1 Virology 78
 - 2.4.1.1 E6/E7 proteins 78
 - 2.4.1.2 Role in cancer 78
 - 2.4.1.3 E2 research 79
 - 2.4.1.4 Latency period 80
 - 2.4.1.5 Clearance..... 80
 - 2.4.2 Diagnosis 81
 - 2.4.2.1 Cervical testing..... 81
 - 2.4.2.2 Oral testing..... 83
 - 2.4.2.3 Testing men..... 83
 - 2.4.2.4 Other testing 84
 - 2.4.3 Market Opportunity Analysis..... 85
- 2.5 Coronavirus 91
 - 2.5.1 Severe acute respiratory syndrome (SARS) 93
 - 2.5.2 Middle East respiratory syndrome (MERS) 95
 - 2.5.3 COVID-19. The SARS CoV 2 Virus..... 96
 - 2.5.3.1 Signs and symptoms..... 97
 - 2.5.3.2 Transmission..... 98
 - 2.5.3.3 Diagnosis 99
 - 2.5.3.4 Prevention 101
 - 2.5.3.5 Management 102
 - 2.5.3.6 Prognosis 103
 - 2.5.4 Pandemic Diagnostics 104

- 2.5.4.1 Risk Management – Spark and Spread 104
- 2.5.4.2 Dx Technology – Nucleic Acid Based..... 106
- 2.5.4.3 Dx Technology - Immunoassay 106
- 2.5.4.4 Time to Market and Preparedness Issues 107
- 2.5.5 COVID-19 Market Opportunity Analysis – A Special Case 107
- 2.5.6 Current COVID-19 DTC Tests..... 108
- 2.6 Influenza 111
 - 2.6.1 Flu..... 113
 - 2.6.1.1 Types of virus 113
 - 2.6.1.2 Influenzavirus A 113
 - 2.6.1.3 Influenzavirus B..... 114
 - 2.6.1.4 Influenzavirus C..... 114
 - 2.6.1.5 Structure, properties, and subtype nomenclature 114
 - 2.6.1.6 Replication..... 115
 - 2.6.2 Testing..... 118
 - 2.6.2.1 Advantages/Disadvantages of Molecular Assays 120
 - 2.6.3 Market Opportunity Analysis..... 121
- 2.7 CT/NG - Chlamydia/Gonorhea 129
 - 2.7.1 Gonorrhea 129
 - 2.7.1.1 Diagnosis 130
 - 2.7.1.2 Screening 130
 - 2.7.2 Chlamydia 130
 - 2.7.2.1 Diagnosis 131
 - 2.7.2.2 Screening 132
 - 2.7.3 Testing..... 133
 - 2.7.3.1 Nucleic acid amplification tests (NAATs). 133

- 2.7.3.2 Performance of NAAT Tests 141
- 2.7.4 Market Opportunity Analysis..... 142
- 2.8 UTI..... 144
 - 2.8.1 Diagnosis 144
 - 2.8.2 Testing..... 146
 - 2.8.2.1 Nitrites test 146
 - 2.8.2.2 Leukocytes test 147
 - 2.8.3 Market Opportunity Analysis..... 148
- 2.9 GAS 149
 - 2.9.1 Infectious Agents 149
 - 2.9.2 Market Opportunity Analysis..... 151
- 2.10 RESP 152
 - 2.10.1 Diagnosis 153
 - 2.10.2 Market Opportunity Analysis..... 154
- 3. Industry Overview 156
 - 3.1 Industry Participants 157
 - 3.1.1 IVD Supplier..... 157
 - 3.1.2 Independent lab specialized/esoteric 158
 - 3.1.3 Independent lab national/regional..... 158
 - 3.1.4 Independent lab analytical 159
 - 3.1.5 Public National/regional lab 159
 - 3.1.6 Hospital lab 159
 - 3.1.7 Physician lab 160
 - 3.1.8 Pharmacies 160
 - 3.1.9 Audit body 161
 - 3.2 The Clinical Laboratory Market Segments..... 163

- 3.2.1 Traditional Market Segmentation..... 163
- 3.2.2 Laboratory Focus and Segmentation..... 164
- 3.2.3 Segmenting the OTC/DTC Market 165
- 3.3 Industry Structure 167
 - 3.3.1 Hospital Testing Share 167
 - 3.3.2 Economies of Scale 167
 - 3.3.2.1 Hospital vs. Central Lab 168
 - 3.3.3 Physician Office Lab's 169
 - 3.3.3.1 The Problem with POLS..... 169
 - 3.3.4 Physician's and OCT/DTC 170
 - 3.3.5 Pharmacies and OCT/DTC 170
 - 3.3.5.1 The Diagnostic Plight of Pharmacies – Trying to do good 170
 - 3.3.5.2 The Theranos Legacy 171
- 4. Market Trends..... 173
 - 4.1 Factors Driving Growth..... 174
 - 4.1.1 Privacy and Anonymity..... 174
 - 4.1.2 The Internet Effect. 174
 - 4.1.3 Rapid Result. 175
 - 4.1.4 The Wellness Movement 175
 - 4.1.5 The COVID-19 Impact..... 175
 - 4.2 Factors Limiting Growth..... 177
 - 4.2.1 Trust Factor 177
 - 4.2.2 Infectious Disease is Declining But..... 179
 - 4.2.3 Wellness Hurts..... 179
 - 4.2.4 Economic Growth improves Living Standards 179
 - 4.3 Diagnostic Technology Development 181

4.3.1 The Multiplex Paradigm Shift..... 181

4.3.2 NAT vs. Lateral Flow 183

4.3.3 The Unusual Role of GPS 183

4.3.4 Self and Send Competition 183

4.4.5 The Relationship to DTC Genetic 185

4.4.6 The Relationship to TeleHealth 185

4.4.7 Sample Collection – Who Knew?..... 185

5. OTC/DTC Infectious Disease Testing Recent Developments 186

Recent Developments – Importance and How to Use This Section..... 187

 Importance of These Developments..... 187

 How to Use This Section 187

FDA Grants EUAs for Direct-to-Consumer Coronavirus Kit..... 187

Stanford Developing Low-Cost, At-Home, COVID-19 Saliva Test 188

Lucira Health Files for \$115M IPO..... 193

Spectrum Solutions Gets CE Mark for Saliva Collection Devices..... 194

Sherlock Biosciences Receives Gates Foundation Grant for COVID-19 Self-Test 194

LabCorp Receives EUA for OTC COVID-19 Test Home Collection Kit 195

FemtoDx Launches Rapid At-Home Test Development for COVID-19 196

FDA approves first at-home coronavirus test 197

Free Home HIV Tests Detect More Infections 198

Biohacking trend supports self testing. 199

PerkinElmer and EverlyWell to Expand U.S. At-Home Health Test Market 200

Mylan, Atomo Diagnostics Get WHO Prequalification Approval for HIV Self-Test 202

OraSure Technologies, Inc. Announces Two Acquisitions..... 202

Nigerian Govt Approves Alere HIV Self-Test Kit 205

Boots launches UTI test and treat service across 37 branches 206

Scanwell Health moves beyond home UTI testing with nationwide kidney disease study partnership 207

Healthy.io raises \$18 million for at-home urinalysis tests 208

LetsGetChecked collects \$30M more for at-home health testing..... 210

TestCard, a \$4 Urine Test Read by Smartphone 212

Digital Health Startup EverlyWell Raises \$50M 212

Thrive adds test-at-home kits for female hormone and cortisol stress 214

Tasso scores \$6.1M for patch-based home blood testing 216

DBS Systems HEMAXIS receives CE/IVD mark..... 218

Abbott HbA1c point-of-care test reliably diagnoses diabetes 219

6. Profiles of Key Diagnostic Testing Companies221

 1DropDiagnostics 222

 Abbott Diagnostics..... 223

 Ador Diagnostics 225

 Akoni Biosystems..... 226

 Alveo Technologies 227

 Applied BioCode 228

 Atomo Diagnostics 229

 Aus Diagnostics..... 230

 Becton, Dickinson and Company..... 231

 Binx Health 233

 Biocartis 234

 bioMérieux Diagnostics 235

 Bio-Rad Laboratories, Inc..... 238

 Bosch Healthcare Solutions GmbH 240

 Cepheid (now Danaher) 241

Curetis N.V. / Curetis GmbH 242

DBS Systems..... 243

Diagenode Diagnostics 244

Diasorin S.p.A. 245

Ellume 246

Everywell 247

Healthy.io 248

Hologic 249

Inflammatix 251

Invetech 252

Janssen Diagnostics 253

Karius 254

Laboratory Corporation of America..... 255

Letsgetchecked 256

Lexogene 257

Luminex Corp..... 258

Mbio Diagnostics 259

Mesa Biotech 260

Mobidiag..... 261

myLabBox..... 262

Mylan..... 263

Nanomix 264

Orasure..... 265

Oxford Nanopore Technologies..... 266

Panagene 267

Primerdesign 268

Prominex..... 269

Qiagen Gmbh 270

Lucira Health..... 272

Quantumdx..... 273

Quest Diagnostics..... 274

Quidel..... 275

Roche Molecular Diagnostics 276

Scanwell Health..... 278

Seegene..... 279

Seventh Sense Biosystems..... 280

Siemens Healthineers 281

T2 Biosystems..... 284

TestCard 285

Thermo Fisher Scientific Inc. 286

Thrive 289

XCR Diagnostics..... 290

7. Global Market Size.....291

7.1 OTC/DTC ID Global Market Size by Country 292

 7.1.1 OTC/DTC ID Global Market Size by Country Table 292

 7.1.2 OTC/DTC ID Global Market Size by Country Chart..... 293

7.2 OTC/DTC ID Global Market Size by Syndrome..... 294

 7.2.1 OTC/DTC ID Global Market Size by Syndrome Table 294

 7.2.2 OTC/DTC ID Global Market Size by Syndrome Share by Year..... 295

 7.2.3 OTC/DTC ID Global Market Size by Syndrome Base vs Final..... 296

 7.2.4 OTC/DTC ID Global Market Size by Syndrome Base Year..... 297

 7.2.5 OTC/DTC ID Global Market Size by Syndrome Final Year 298

- 7.2.6 OTC/DTC ID Global Market Size by Syndrome Segment Growth..... 299
- 7.3 OTC/DTC ID Global Market Size by Channel 300
 - 7.3.1 OTC/DTC ID Global Market Size by Channel Table 300
 - 7.3.2 OTC/DTC ID Global Market Size by Channel Share by Year 301
 - 7.3.3 OTC/DTC ID Global Market Size by Channel Base vs Final 302
 - 7.3.4 OTC/DTC ID Global Market Size by Channel Base Year 303
 - 7.3.5 OTC/DTC ID Global Market Size by Channel Final Year..... 304
 - 7.3.6 OTC/DTC ID Global Market Size by Channel Segment Growth 305
- 8. Global Market by Syndrome306
 - 8.1 Respiratory Market (including COVID-19) 307
 - 8.1.1 Respiratory Market by Country Table 307
 - 8.1.2 Respiratory Market Chart..... 308
 - 8.2 STD Market 309
 - 8.2.1 STD Market by Country Table 309
 - 8.2.2 STD Market Chart..... 310
 - 8.3 UTI Market..... 311
 - 8.3.1 UTI Market by Country Table 311
 - 8.3.2 UTI Market Chart 312
 - 8.4 HxV Market..... 313
 - 8.4.1 HxV Market by Country Table 313
 - 8.4.2 HxV Market by Chart..... 314
 - 8.5 Other Market..... 315
 - 8.5.1 Other Market by Country Table 315
 - 8.5.2 Other Market Chart..... 316
- 9. Global Market by Channel317
 - 9.1 OTC Market 318

9.1.1 OTC Market by Country Table..... 318

9.1.2 OTC Market Chart 319

9.2 DTC Market 320

9.2.1 DTC Market by Country Table 320

9.2.2 DTC Market Chart..... 321

9.3 HSG Market 322

9.3.1 HSG Market by Country Table 322

9.3.2 HSG Market Chart 323

Appendices324

I. United States Medicare System: 2021 Clinical Laboratory Fees Schedule 324

II. FDA Approved Microbial Tests..... 418

Table of Tables

Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 (\$Billion) 34

Table 2 Classification of HIV Species..... 37

Table 3 HBV Tests - CMS Codes & Prices 67

Table 4 HCV Tests - CMS Codes & Prices 74

Table 5 HPV Clearance Rates 81

Table 6 HPV Tests - CMS Codes & Prices 86

Table 7 HPV Tests, Technology, Types 87

Table 8 Characteristics of Coronavirus Pandemic Infections 96

TABLE 9 COVID-19 SYMPTOMS 98

Table 10 DTC COVID-19 TESTS and CURRENT STATUS 109

Table 11 Types of Influenza Tests 118

Table 12 Influenza Tests - CMS Codes & Prices..... 121

Table 13 FDA Cleared Molecular Assays for Influenza 122

Table 14 FDA Cleared NAAT CTGC Tests 134

Table 15 CTGC NAAT Target Sequences and Possible False Reactions 139

Table 16 CT/NG Tests - CMS Codes & Prices 143

Table 17 GAS Panel BioFire 151

Table 18 BioFire RESP Panel..... 154

Table 19 Market Players by Type 157

Table 20 Clinical Laboratory Departments and Segments 163

Table 21 Laboratory Management Focus – Different Approaches 164

Table 22 Key Segmentation Variables Going Forward..... 165

Table 23 Possible Market Segments of OTC/DTC Market 165

Table 24 Five Factors Driving Growth 174

Table 25 Four Factors Limiting Growth 177

Table 26 Self vs. Send TAT 184

Table 27 OTC/DTC ID Global Market by Country/Region 292

Table 28 OTC/DTC ID Global Market by Syndrome 294

Table 29 OTC/DTC ID Global Market by Channel 300

Table 30 Respiratory Syndrome by Country 307

Table 31 STD Testing market by country 309

Table 32 UTI Testing market by country 311

Table 33 HxV Testing market by country 313

Table 34 Other Testing market by country 315

Table 35 OTC Market by Country 318

Table 36 DTC market by country 320

Table 37 HSG market by country 322

Table 38 2021 Clinical Lab Fee Schedule 324

Table of Figures

Figure 1 Medicare Clinical Lab Expenditures 2014 to 2024 (\$Million) 33

Figure 2 HIV Virion 38

Figure 3 Diagram of the HIV Replication Cycle 42

Figure 4 The Structure of the HBV Virus..... 61

Figure 5 Hepatitis B Replication 62

Figure 6 Structure of the HCV Virus..... 69

Figure 7 HCV Replication Cycle 72

FIGURE 8 STRUCTURE OF CORONAVIRUSES 92

Figure 9 Structure of the Influenza Virion 115

Figure 10 Influenza Replication..... 116

Figure 11 Chart Death Rates and Infectious Disease Decline 178

Figure 12 The Multiplex Paradigm Shift..... 182

Figure 13 Market Size by Country - Key Countries..... 293

Figure 14 Chart of Global Market by Syndrome by Year 295

Figure 15 Syndrome Segment Shares Base vs Final..... 296

Figure 16 Syndrome Share Base Year..... 297

Figure 17 Syndrome Share Final Year 298

Figure 18 Syndrome Segment Growth Rates..... 299

Figure 19 Chart of Global Market by Channel by Year..... 301

Figure 20 Channel Segment Shares Base vs Final 302

Figure 21 Channel Share Base Year 303

Figure 22 Channel Share Final Year 304

Figure 23 Channel Segment Growth Rates 305

Figure 24 Chart - Respiratory market Growth 308

Figure 25 Chart – STD market Growth 310

Figure 26 Chart – UTI market Growth..... 312

Figure 27 Chart - HxV market Growth 314

Figure 28 Chart – Other market Growth 316

Figure 29 Chart - OTC market Growth 319

Figure 30 Chart – DTC market Growth 321

Figure 31 Chart – HSG market Growth..... 323